Drug Trial News

RSS

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Cefpodoxime not effective in treating uncomplicated cystitis in women

Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Anticoagulation drugs can prevent PE, DVT after total joint replacement

Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.

7 Feb 2012

Top-line results from Merck's vorapaxar clinical study on thrombosis

Merck, known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar.

7 Feb 2012

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research. In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers.

7 Feb 2012

Three new targeted drugs can lead to fatal cancer complications

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients.

7 Feb 2012

Merck completes two suvorexant Phase III trials on insomnia

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia.

7 Feb 2012

COC pill alleviates symptoms of painful menstrual periods

A large Scandinavian study, that has been running for 30 years, has finally provided convincing evidence that the combined oral contraceptive pill does, indeed, alleviate the symptoms of painful menstrual periods reports scientists from the University of Gothenburg, Sweden.

7 Feb 2012

FDA clears Neurelis IND to commence NRL-1 clinical trials for acute breakthrough seizures

Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.

7 Feb 2012

Preliminary results from Remedy Pharmaceuticals' RP-1127 Phase 2 trial on stroke

Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little. Some will die; a number will suffer debilitating aftereffects. Now, preliminary results of a Phase 2 clinical trial using Remedy Pharmaceuticals' new drug, RP-1127, presented at the 2012 International Stroke Conference in New Orleans on February 2, offer hope to many of these patients.

6 Feb 2012

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

Orexigen reaches SPA agreement for Contrave outcomes trial with FDA

Orexigen Therapeutics, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the Contrave outcomes trial.

6 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

Neutra to initiate clinical trials of new all-natural weight-loss supplement

Neutra Corp., an emerging nutraceuticals provider, expects to begin clinical trials of its eagerly anticipated new all-natural weight-loss supplement as early as this week when the company's first batch of Pure Plus arrives from the manufacturer.

6 Feb 2012

African scientists' search for female-controlled microbicide gel to prevent HIV continues

AllAfrica.com examines efforts by African researchers to develop a female-controlled HIV prevention method, writing, "Scientists searching for a gel or vaccine that can prevent HIV infection ride a rollercoaster of hope and disappointment." The article profiles efforts by researchers from the Centre for the AIDS Program of Research in South Africa (Caprisa) to find a microbicide gel to protect women from HIV infection.

4 Feb 2012

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

G-CSF's AX200 does not improve stroke-related disability

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Drug Trial News

Routine 4CMenB immunizations effective against meningococcal strains in infants

Cefpodoxime not effective in treating uncomplicated cystitis in women

Anticoagulation drugs can prevent PE, DVT after total joint replacement

Top-line results from Merck's vorapaxar clinical study on thrombosis

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Three new targeted drugs can lead to fatal cancer complications

Merck completes two suvorexant Phase III trials on insomnia

COC pill alleviates symptoms of painful menstrual periods

FDA clears Neurelis IND to commence NRL-1 clinical trials for acute breakthrough seizures

Preliminary results from Remedy Pharmaceuticals' RP-1127 Phase 2 trial on stroke

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

Orexigen reaches SPA agreement for Contrave outcomes trial with FDA

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

Neutra to initiate clinical trials of new all-natural weight-loss supplement

African scientists' search for female-controlled microbicide gel to prevent HIV continues

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

G-CSF's AX200 does not improve stroke-related disability

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News